Introduction

Oncology Reports

1021-335X 1791-2431

D.A. Spandidos

10.3892/or.2019.7179

OR-0-0-7179

Articles

Effects of gossypol on apoptosis-related gene expression in racially distinct triple-negative breast cancer cells

Messeha

Samia S.

Zarmouh

Najla O.

Mendonca

Patricia

Alwagdani

Hayfaa

Cotton

Carolyn

Soliman

Karam F.A.

College of Pharmacy and Pharmaceutical Science, Florida A&M University, Tallahassee, Florida 32307, USA

Correspondence to: Dr Karam F.A. Soliman, Division of Basic Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, 104 Dyson Pharmacy Building, 1520 S. Martin Luther King Boulevard, Tallahassee, FL 32307-3102, USA, E-mail: karam.soliman@famu.edu

08 2019

31 05 2019

42 2 467 478 24122018 12042019

2019

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Apoptosis is a gene-directed mechanism that regulates cell proliferation and maintains homeostasis. Moreover, an aberrant apoptotic process can lead to several pathological conditions, such as tumorigenesis and cancer metastasis. In the present study, the apoptotic effect of the natural polyphenol compound gossypol (GOSS) was investigated in triple-negative breast cancer (TNBC) cells. The effect of GOSS was evaluated in two cell lines representative of a Caucasian-American and African-American origin, MDA-MB-231 (MM-231) and MDA-MB-468 (MM-468), respectively. A similar response to both cytotoxicity and proliferation was observed in the two cell lines. However, MM-468 cells were 2-fold more sensitive to the apoptotic effect of the compound, which was accompanied by a longer delay in colony formation. Furthermore, GOSS was found to alter the mRNA expression of many apoptosis-related genes. The compound significantly upregulated growth arrest and DNA damage-inducible 45 alpha protein (GADD45A), tumor necrosis factor receptor superfamily 9 (TNFRSF9) and BCL2 interacting protein 3 (BNIP3) in MM-231 cells. Similarly, GADD45A and BNIP3 were upregulated in MM-468 cells. A significant finding in this study is the profound 159-fold increase in TNF gene expression that was observed in MM-468 cells. Moreover, the apoptosis-suppressor gene baculoviral IAP repeat containing 5 (BIRC5) was significantly repressed (by more than 90%) in both cell lines, as well as death-associated protein kinase 1 (DAPK1) in MM-231 cells and tumor protein 73 (TP73) in MM-468 cells. In conclusion, the data obtained in this study provide a molecular understanding of the GOSS-induced apoptosis effect and suggest the importance of this polyphenol compound targeted towards TNBC treatment, particularly in African-American women.

gossypol breast cancer gene expression apoptosis

Introduction

In normal cells, apoptosis is a genetically controlled process involving several pathways regulating development and maintaining homeostasis (1,2). Defects in apoptotic pathways can lead to pathological conditions such as malignancy, metastasis and chemotherapy resistance (3). Apoptosis is mediated by two basic pathways: Extrinsic (death receptor-mediated) and intrinsic (mitochondrial or Bcl-2-regulated). Initiation of the extrinsic apoptotic pathway requires the interaction of ligands such as tumor necrosis factor α (TNF-α) and fatty acid synthase (FAS) with their transmembrane receptors (4,5). In particular, the intrinsic pathway maintains the balance between antiapoptotic and proapoptotic proteins (6). To resist apoptosis, cancer cells either upregulate the expression of antiapoptotic proteins such as Bcl-2 and Bcl-xL or downregulate the expression of proapoptotic proteins such as Bax and Bak, and both proteins are regulated by the p53 tumor-suppressor gene (7). Moreover, in an aggressive malignant phenotype, the overexpressed Bcl-2 protein prevents the release of cytochrome c from the mitochondrial membrane, which leads to interruption of the intrinsic apoptotic signaling pathway and prevents apoptotic cell death (8). Similarly, in many types of cancer, the overexpression of inhibitor of apoptosis (IAP) family members is a challenge in chemoresistance (9) and is considered a therapeutic target in apoptosis-inducing strategies (10).

Breast cancer (BC) is the most commonly diagnosed cancer and the second leading cause of death among women in the United States (11). BC is commonly classified according to the gene expression profile, and the triple-negative breast cancer (TNBC) subgroup is the most aggressive and metastatic, representing approximately 10–15% of all BC cases (12). TNBC is known to be more common among African-American (AA) patients than Caucasian American (CA) patients (2). Indeed, TNBC treatment options are limited because of the absence of the three characteristic receptors: Estrogen (ER), progesterone (PR) and human epidermal growth factor (Her2/neu) (13,14). Although TNBC has initial higher response rates to a variety of chemotherapy agents (15), approximately 30% of patients present with a poor prognosis, and treatment failure leads to a median survival of 1 year (16).

Many studies have demonstrated the medicinal importance of the polyphenol compound gossypol (GOSS), a minor constituent of cotton (Gossypium hirsutum L.) seeds (17–19). GOSS has been used in China as a male contraceptive, as well as for treating malaria and viral infections (20,21). GOSS has been suggested to be a potent anticancer agent against BC (22). Indeed, the antiproliferative and anti-metastatic effects of GOSS have been demonstrated in several human cancers, including leukemia (23), glioma (24), colon (25), prostate (26), adrenal (27) and breast cancer (28–30). The antiproliferative effect of GOSS is mediated through the induction of cellular apoptosis (31). Furthermore, the apoptotic effect of the compound was detected in different human cells, including multiple myeloma (32,33), synovial sarcoma (34) pharynx, tongue and salivary gland (35), prostate (36–38), colon (39), ovarian (40,41) gastric (42), leukemia (43,44) and pituitary (45), in addition to breast (31,46). In cancer therapy, the combination of multiple agents is key to overcoming the resistance mechanisms of the tumor (47), and GOSS has been found to induce an apoptotic effect in various human cancer cells in combination with low doses of taxanes (46), doxorubicin (34), dexamethasone (43) and valproic acid (36).

Therefore, the present study was designed to examine the effect of the natural compound GOSS on two human TNBC cell lines, MDA-MB-231 (MM-231) and MDA-MB-468 (MM-468), representing the CA and AA races, respectively (48). In the present study, we investigated the effect of GOSS on cell viability, proliferation and colony formation. We hypothesized that GOSS alters the expression of different apoptosis-related genes that mediate the antiproliferative effect of GOSS. The present study enhanced our understanding of events associated with cell death following GOSS treatment.

Materials and methods <sec> <title>Materials and reagents

GOSS (purity ≥90%), doxorubicin (purity ≥99%), and cell culture flasks were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Trypsin-EDTA solution and Alamar Blue^® (a solution of resazurin fluorescence dye) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Dimethyl sulfoxide (DMSO), penicillin/streptomycin and Dulbecco's phosphate-buffered saline (DPBS) were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). Dulbecco's modified Eagle's medium (DMEM), heat-inactivated fetal bovine serum (FBS), and cell culture plates were purchased from VWR International (Radnor, PA, USA). An Annexin V-FITC Apoptosis Detection Kit Plus (cat. no. 68FT-Ann VP-S) was purchased from RayBiotech (Norcross, GA, USA). A DNA-free™ kit (cat. no. AM1907) was purchased from Life Technologies, Inc. (Thermo Fisher Scientific, Inc., Waltham, MA, USA). An iScript™ cDNA Synthesis kit (cat. no. 170-8890), SsoAdvanced™ Universal SYBR^® Green Supermix and the Human Apoptosis PCR array (SAB Target List) H96 were purchased from Bio-Rad Laboratories (Hercules, CA, USA).

Cell culture

Two TNBC cell models, MM-231 and MM-468, were purchased from the American Type Culture Collection (ATCC). Both cell lines were grown in 75-ml tissue culture (TC) flasks at 37°C in a humidified 5% CO₂ incubator and subcultured as needed with trypsin/EDTA (0.25%). The DMEM contained 4 mM L-glutamine and was supplemented with 10% heat-inactivated FBS (v/v) and 1% penicillin/streptomycin salt solution (100 U/ml and 0.1 mg/ml, respectively). The DMEM was supplemented with 2.5% heat-inactivated FBS.

Cell viability assay

In this study, cells were plated at a density of 5×10⁴ cells/well in 96-well plates and incubated overnight at 37°C. GOSS was solubilized in dimethyl sulfoxide (DMSO), and both types of cells were treated for 24 h with the compound (concentration ranges of 0–100 µM in MM-231 cells and 0–50 µM in MM-468 cells). Control wells were treated with DMSO at the highest concentration used (<0.1%), and wells treated in the same manner but without cells were used as blanks. In this study, Alamar Blue^® was used to determine the cell viability as previously described (49). The fluorescent fuchsia-reduced resazurin dye was measured at an excitation/emission wavelength of 530/590 nm using a Synergy HTX Multi-Mode microplate reader (BioTek Instruments, Inc., Winooski, VT, USA).

Cell proliferation and clonogenic assays

The inhibition of cell proliferation by GOSS was determined for MM-231 and MM-468 TNBC cells based on the dose-response viability study concentrations (50) using Alamar Blue^®. Briefly, cells were plated at an initial density of 1×10⁴ cells/well in 96-well plates and incubated overnight at 37°C. The cells were treated for 96 h with GOSS at concentrations ranging from 0 to 100 µM in MM-231 cells and from 0 to 50 µM in MM-468 cells in a final volume of 200 µl/well. Control cells were exposed to DMSO at a concentration of <0.1%, and equivalent wells without cells were used as a blank. Doxorubicin was used as a positive control at concentrations ranging from 0 to 10 µM in both cell lines. Proliferation was measured at different intervals up to 96 h for GOSS-treated cells and at 72 h for doxorubicin-treated cells (51) by adding Alamar Blue^® as previously described (49). The plates were read at an excitation/emission wavelength of 530/590 nm.

A clonogenic assay was performed to measure the long-term effect of GOSS on MM-231 and MM-468 TNBC cells. Both cell lines were seeded and treated similarly to the proliferation study described above. After either a 1- or a 6-h exposure period, the GOSS-containing experimental media were replaced by growth media after washing the cells with DPBS. The cells were allowed to grow for 7 days, and the colonies formed in both treated and untreated cells were then evaluated based on the reduction of Alamar Blue^® as previously described in the Cell viability assay.

Apoptosis assay

The apoptotic effect of GOSS was determined in MM-231 and MM-468 cells. Briefly, each cell line was seeded at an initial concentration of 5×10⁵ cells/well in 6-well plates and incubated overnight at 37°C. To induce apoptosis, cells were treated for 24 h with GOSS at concentrations ranging from 0 to 100 and from 0 to 50 µM in MM-231 and MM-468 cells, respectively, in a final volume of 3 ml/well of experimental media. Control cells were exposed to DMSO at a concentration of <0.1%. After the 24-h incubation period, treated and control cells from each well were harvested, pelleted and washed in phosphate-buffered saline (PBS). According to the manufacturer's protocol, the cell pellets were resuspended in 500 µl of the provided 1X Annexin V binding buffer and labeled with 5 µl each of Annexin V-FITC and propidium iodide (PI). The apoptotic effect was quantified within 5–10 min on a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA). For each sample, 1×10⁴ cells were examined and CellQuest software (BD Biosciences) was used for acquisition and data analysis.

Reverse transcription-polymerase chain reaction (RT-PCR) apoptosis array

This experiment was performed based on the data of the apoptosis assay using the concentrations that did not cause a considerable necrosis effect in either cell line: 25 µM in MM-231 cells and 20 µM in MM-468 cells. Briefly, two T-75 flasks of 10×10⁶ cells (control and treated for each cell line) were incubated overnight at 37°C and for an additional 24-h in the absence or presence of the previously indicated concentrations of the test compound. The cells from each sample were pelleted and mixed with 1 ml of TRIzol reagent to isolate total RNA. Subsequently, 0.2 ml of chloroform was added to each sample, vortexed, incubated at room temperature (RT) for 2–3 min and centrifuged for 15 min at 10,000 × g and at 2–8°C. The aqueous phase was collected and mixed with 0.5 ml of isopropyl alcohol to precipitate the RNAs. The RNA pellets were then dissolved in ~30–50 µl of Nuclease-free water to measure RNA quantity and quality in each sample using a NanoDrop spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc.). Finally, cDNA representing the control or treated cells was synthesized using the iScript™ cDNA Synthesis kit according to the manufacturer's protocol. The obtained cDNA was reconstituted in Nuclease-free water, and the 96-well apoptosis array was loaded with 10 µl each of the reconstituted cDNA (2.3 ng) and SsoAdvanced™ Universal SYBR^® Green Supermix (Bio-Rad Laboratories) and then placed for 5 min in a shaker and centrifuged at 1,000 × g for 1 min. The PCR run was established with 39 cycles of denaturation as follows: 30-sec activation at 95°C, 10-sec denaturation at 95°C; 20-sec annealing at 60°C; and 31-sec extension at 65°C using a Bio-Rad CFX96 Real-Time System (Bio-Rad Laboratories). All real-time PCRs were performed in triplicate for each cell line. Gene expression was analyzed using the CFX 3.1 Manager software (Bio-Rad Laboratories) and verified with Student's t-test.

Statistical analysis

Data for this study were analyzed using GraphPad Prism 6.2 software (GraphPad Software, Inc., San Diego, CA, USA). All data points were obtained from the average of at least two independent studies and are expressed as the mean ± SEM. For the viability assay, IC₅₀ values were determined by non-linear regression with the R² best fit and the lowest 95% confidence interval. In both the viability and apoptosis assays, the significance of the difference between each control and its related treatment group was determined using one-way analysis of variance (ANOVA) followed by Bonferroni's multiple comparison test. For both the proliferation and clonogenic assays, the statistical analysis was performed with two-way analysis of variance (ANOVA) between each exposure period and other(s) followed by Bonferroni's multiple comparison test. Overall, a difference was considered significant at *P<0.05 and ****P<0.0001 (as indicated in the figures and legends). Gene expression was analyzed using CFX 3.1 Manager software (Bio-Rad Laboratories) and verified with the Student's t-test.

Results

The anticancer effects of GOSS were examined in both MM-231 and MM-468 cell lines. As indicated in Fig. 1A and B, a highly significant effect (P<0.0001) of GOSS on cell viability was found in MM-231 and MM-468 cells at different concentrations of the compound (6.3–100 and 10–50 µM in MM-231 and MM-468, respectively). In both cell lines, the obtained IC₅₀ did not show a significant difference in response to the compound (IC₅₀=22.52±0.67 and 24.6±1.79 µM for MM-231 and MM-468 cells, respectively).

To measure the growth inhibitory potency of GOSS in MM-231 and MM-468 cell lines, both antiproliferative and clonogenicity assays were performed. In both cell lines, GOSS inhibited cell proliferation and colony formation in a dose- and time-dependent manner compared to the control cells (Fig. 2). The inhibition of cell proliferation, as indicated by the reduction of resazurin and verified by the decrease in the IC₅₀ values at the different periods of exposure, is shown in Fig. 2A and C (MM-231 and MM-468 cells, respectively). Indeed, the IC₅₀ values were reduced significantly (P<0.0001), from 23.17 to 5.34 µM in MM-231 cells and from 28.53 to 8.05 µM in MM-468 cells at the 24-vs. 96-h exposure periods. Furthermore, in both cell lines, GOSS significantly inhibited cell proliferation (P<0.0001) at the 24-h treatment period vs. other periods, but there was no significant difference in cell proliferation inhibition between the 72-vs. 96-h treatment period.

The data also showed that GOSS significantly inhibited colony formation in both MM-231 and MM-468 cells (Fig. 2B and D). In MM-231 cells, a significant delay in colony formation (P<0.0001) was observed between the 1- vs. the 6-h exposure periods following treatment with 12.5 and 25.0 µM GOSS (Fig. 2B). A significant difference was also observed in its counterpart cell line, MM-468 (P<0.05-P<0.0001), throughout the concentration range of 5–30 µM, as shown in Fig. 2D.

Nonetheless, the data indicate that GOSS has similar growth inhibitory potency on both racially distinct cell lines. The colony formation assessment indicated that after a 6-h treatment period, GOSS was ~2-fold more effective in MM-468 cells (IC₅₀=6.68±1.67 µM) than in MM-231 cells (IC₅₀=12.33±0.003 µM) (Fig. 2B and D).

On the other hand, the IC₅₀ value of cells after 72 h of exposure to doxorubicin was 1.69±0.11 and 0.23±0.003 in MM-231 and MM-468 cells, respectively, with P<0.05-P<0.0001 (Fig. 3). The apoptotic effect of GOSS on both MM-231 and MM-468 TNBC cells was examined to confirm apoptosis mediation of the antiproliferative effect and colony formation inhibition of GOSS. After 24 h of exposure, a gradual but significant increase in the number of apoptotic cells (P<0.0001) was observed in a dose-dependent manner (Fig. 4A and B). Additionally, the results indicated that MM-468 cells were more sensitive (almost 2-fold more sensitive) to GOSS than MM-231 cells, and 90% of the MM-468 cells analyzed were in the apoptotic phase following treatment with 50 µM GOSS, as shown in Fig. 4B, whereas <60% of MM-231 cells analyzed exhibited apoptotic effects at 100 µM (Fig. 4A). The obtained data show the strong apoptotic effect of GOSS on both TNBC cell lines.

Quantitative real-time PCR (qRT-PCR) was performed in both GOSS-treated cell lines to identify the genes related to GOSS-induced apoptosis. The profiling of normalized mRNA expression in both cell lines provided insights into the influence of the compound on many apoptosis-related genes. In this study, we identified apoptosis-related genes that were significantly upregulated/downregulated by the compound. Overall, in both cell lines, as shown in Fig. 5A and B, the visually recognized red dots represent the upregulated genes, while the green dots represent those that were downregulated by GOSS.

The specifically impacted genes were quantified and are presented in Figs. 6 and 7. In MM-231 cells, GOSS significantly (P<0.05) increased the expression of three genes (GADD45A, TNFRSF9 and BNIP3) (Fig. 6). Similarly, in MM-468 cells, GADD45A and BNIP3 were upregulated by GOSS treatment (P<0.05-P<0.01) (Fig. 7). Nevertheless, the GADD45A gene was significantly upregulated in both cell lines; the fold-increase in MM-231 cells was 33.42 and that in MM-468 cells was 9.22 (Table I). Moreover, the measured upregulation of BNIP3 in MM-231 cells was approximately twice that of its counterpart cell line, MM-468 (Figs. 6 and 7 and Table I). Two members of the TNF/receptor family of genes were also increased. TNF was profoundly overexpressed by 159-fold in MM-468 cells, and an ~12-fold increase in the TNF receptor TNFRSF9 was found in MM-231 cells. In contrast, GOSS significantly repressed the mRNA expression of many apoptosis-related genes (P<0.05-P<0.001). More than 90% inhibition (≥8-fold decrease) in BIRC5 was observed in both cell lines, in addition to a 14.79- decrease and an 8.65-fold decrease in DAPK1 and TP73 in MM-231 and MM-468 cells, respectively (Table I). Notably, the compound GOSS did not show a significant effect on the expression of the different caspases (data not shown).

Discussion

Apoptosis is a pivotal cellular process that maintains genomic integrity (52). Genomic alterations, including the upregulation of genes involved in DNA synthesis, cell division, proliferation, and cell cycle progression, have been shown to be key mediators in BC development and progression. (53,54). In particular, the apoptosis methylation-mediated silencing of genes is the most important epigenetic mechanism for regulating normal gene expression (1).

The present study provides evidence for the anticancer effect of the natural polyphenol gossypol (GOSS) in two triple-negative breast cancer (TNBC) cell lines: MDA-MB-231 (MM-231) and MDA-MB-468 (MM-468). However, future studies are needed to determine the relative toxicity of GOSS in TNBC cells compared to non-cancer cells. This compound impacted the molecular apoptotic pathway by altering the mRNA gene expression of specific apoptosis-related genes (Figs. 5–7 and Table I). Overall, the obtained data are consistent with those from previous studies (22,29,35). This study shows similar cytotoxic (Fig. 1A and B) and antiproliferative (Fig. 2A and C) effects in both cell lines. Notably, MM-468 cells showed a higher response during the colony formation (Fig. 2B and D), doxorubicin antiproliferation (Fig. 3) and apoptotic (Fig. 4) assays. However, doxorubicin was an extremely potent antiproliferative agent, and the obtained IC₅₀ values were compatible with those previously reported (51). However, meager previous investigations have examined GOSS effects on diet, and a previous study on women with refractory metastatic breast cancer (BC) indicated that the maximally tolerated dose of GOSS was 40 mg/day (55).

In normal cells, several molecular pathways control apoptosis and orchestrate the balance between cell proliferation and cell death to maintain homeostasis. However, in cancer cells, triggering the genes involved in these signaling pathways leads to uncontrolled cell proliferation and tumorigenesis. Therefore, understanding the mechanisms of apoptosis and targeting the expression of these apoptotic genes are crucial in the development of targeted cancer therapy (56). The profiling of apoptosis-related genes in both MM-231 and MM-468 TNBC cell lines revealed that GOSS could induce both intrinsic and extrinsic apoptotic pathways. In the present study, GOSS was found to upregulate the proapoptotic genes GADD45A, BNIP3, TNF and TNFRSF9, the critical initiators of the extrinsic apoptotic pathway. Moreover, the compound was efficiently able to attenuate the expression of the survivin BIRC5 gene, a well-known inhibitor of intrinsic apoptosis, as well as two additional proapoptotic genes, DAPK1 and TP73. Although GOSS increased GADD45A expression in both cell lines, the gene was highly upregulated in MM-231 cells (33-fold increase) compared with MM-468 cells (Table I). The proapoptotic gene, growth arrest and DNA damage-induced 45 alpha (GADD45A) is a member of the stress sensor family GADD45, which normally controls many cellular functions, including DNA repair, apoptosis, cell cycle regulation and genotoxic stress (57). However, GADD45 genes are epigenetically inactivated in different types of cancer cells (1). In TNBC, there is a strong association between a low level of the GADD45A gene and the lack of the three hormone receptors, ER, PR and Her2/neu (58). Moreover, in BC, the hypermethylated GADD45A gene is regulated by two major tumor suppressor proteins: p53 and BRCA1 (59). Furthermore, the upregulation of GADD45A may be involved in apoptosis by activating the JNK and/or p38 MAPK signaling pathways (60,61).

In both MM-231 and MM-468 cell lines, GOSS upregulated BNIP3 expression. However, the increase in gene expression in MM-231 cells was ~2-fold greater than that in its counterpart cell line, MM-468 (Figs. 6 and 7 and Table I). The death-inducing mitochondrial protein BNIP3 is a member of the proapoptotic Bcl-2 family of proteins that promotes both apoptosis and autophagy. BNIP3 contains a C-terminal transmembrane (TM) domain as well as a sequence resembling a BH3 domain, and both are essential for apoptosis induction (62,63). Moreover, BNIP3 mediates novel necrosis-like mechanisms by opening the mitochondrial permeability transition (PT) pore independent of caspase activation, cytochrome c release, Apaf-1, or the nuclear translocation of apoptosis-inducing factor (64). Similar to our finding, in BC, the induction of BNIP3 was found to induce apoptosis via (FAS) inhibition, which leads to the suppression of cell proliferation (63,65).

Various stimuli can trigger apoptosis, one of which is the signaling protein TNF superfamily (66). In the present study, TNF, also known as the TNF-α gene (67), was the most upregulated in MM-468 cells. The compound GOSS markedly increased the expression of TNF by 159-fold (Fig. 7 and Table I). The fact that TNF is the most potent inducer of apoptosis in the TNF superfamily (68) can explain the higher response of MM-468 cells to the apoptotic effect induced by the compound. Furthermore, multifunctional TNF can trigger both cell proliferation and cell death. In particular, the upregulation of NF-κB-related genes increases cell viability and proliferation. However, the activation of different caspases leads to apoptosis induction (68,69). Contrary to healthy cells, the multifunctional proinflammatory gene TNF-α is detected in many cancers, including ovarian, renal and breast (70–72), and has been found to increase cell survival and proliferation through NF-κB activation (73). Additionally, the TNF superfamily also plays a crucial role in regulating tissue homeostasis by activating the extrinsic apoptotic pathway (74) and triggering various signaling pathways, including the activation of caspases, impacting proliferation and inducing apoptosis (75).

In MM-231 cells, a 12-fold upregulation in TNF receptor superfamily 9 (TNFRSF9 also known as CD137, 4–1BB, or ILA) was found (Fig. 5 and Table I). TNFRSF9 is a costimulatory receptor that is involved in apoptosis. TNFRSF9 is expressed by activated monocytes and lymphocytes (76), while its ligand is expressed by monocytes and B cells (3). In MM-231 cells, the most important ability is for CD137 to synergize the apoptotic effect of suberoylanilide hydroxamic acid (SAHA), a histone deacetylase (HDAC) inhibitor with anticancer properties (77).

GOSS markedly and similarly decreased the expression of BIRC5 in both TNBC cell lines, as shown in Figs. 5 and 6 and Table I. BIRC5, or the survivin gene is the smallest member of the IAP family (78). In the human genome, the gene encoding BIRC5 is among one of the highly specific tumor genes (79) that prevent apoptosis by inhibiting the activity of different caspases (80), leading to aggressive tumor behavior and poor clinical outcomes (81). Compared to normal tissues, an increase in BIRC5 expression has been demonstrated in different types of cancers, including pancreatic (82), lung (83), colon and ovarian (84), esophageal and skin (85), colorectal and lymphoma (86) and prostate (87). In particular, in TNBC cells, the highly expressed BIRC5 is considered a marker in the early diagnosis of BC and was found to correlate with the resistance to radiation and chemotherapy (79,81,84). Additionally, two more apoptosis-related genes, DAPK1 and TP73, were significantly downregulated in GOSS-treated MM-231 and MM-468 cells, respectively (Figs. 6 and 7 and Table I).

The proapoptotic death-associated protein kinase 1 (DAPK1) is characterized by its C-terminal death domain and plays an essential role in cell survival, proliferation and death (88). Compared to normal cells, lower expression of DAPK1 mRNA has been observed in different cancer cell lines; however, in the presence of TNF-α, the gene can decrease cell growth (89). The present study indicated repression of DAPK1 gene expression in treated MM-231 cells. In addition, TNF-α-stimulated apoptosis was inhibited by overexpression of DAPK1 (89). Taken together, our results suggest that DAPK1 downregulation may be a promising target in cancer therapy, particularly in MM-231 TNBC cells.

Surprisingly, the compound GOSS downregulated the gene TP73 in MM-468 cells. Tumor protein p73 (TP73) is a member of the TP53 (p53) tumor-suppressor gene family. This family is characterized by a proapoptotic role (90) and is involved in cell cycle regulation and apoptosis (91). In TNBC MM-231 cells (92,93), upregulated TP73 can replace (92) or activate P53 gene transcription, induce apoptosis and considerably affect tumor progression (94). On a molecular basis, gene polymorphisms can modify their specific functions (95). Certainly, there is an association between the TP73 polymorphism (G4C14-A4T14) and cancer risk (94). Although it was not found in BC, in sympathetic neurons, the p73 isoform lacking the transactivation domain has been found to act as a neuronal antiapoptotic protein and counteract the proapoptotic function of p53 (90).

The data obtained in this study provide evidence that the apoptotic effect of GOSS is related to either the upregulated proapoptotic genes and TNF-α or repression of the inhibitor of apoptosis genes or both. However, previous studies have shown the ability of GOSS to induce apoptotic effects by DNA fragmentation (96), DNA synthesis inhibition (30), and arresting S-phase without affecting RNA and protein synthesis (97). The molecular mechanism of GOSS-induced apoptosis was previously determined to be associated with the interaction between the compound and the antiapoptotic proteins Bcl-2 and Bcl-xl in the mitochondria (98). In other words, the BH3 mimetic GOSS ectopically expresses Bcl-2 and Bcl-xL (25), inhibiting the Bcl-2/Mcl-1 pathway (33) and the heterodimerization of Bcl-xL/Bcl-2 by releasing proapoptotic proteins (apoptosis-inducing factor, AIF) (37). GOSS can also induce apoptosis by releasing cytochrome c and activating the proapoptotic protein Bak or Bax/Bak via conformational changes in overexpressed Bcl-2 (99,100). Moreover, inhibiting the phosphorylation of ERK1/2 and AKT, stimulating p38 and JNK1/2 protein phosphorylation, and inhibiting ErbB2 protein expression have been found to be mechanisms of GOSS-induced apoptosis (35).

In conclusion, the present study elucidated the genes involved in the apoptotic molecular mechanism of the polyphenol compound GOSS in two different TNBC cell models, MM-231 and MM-468. This study demonstrated that GOSS was more potent in MM-468 cells in inducing apoptosis and delaying colony formation. However, the impact of the compound on cell viability and proliferation was almost the same, and the data obtained did not show a considerable difference in cell response. In parallel, GOSS upregulated two proapoptotic genes (GADD45A and BNIP3) and attenuated the expression of BIRC5 in both MM-231 and MM-468 cells. Additionally, GOSS increased the expression of TNFRSF9 and repressed DAPK1 in MM-231 cells, while an increase in TNF gene expression (159-fold) and repression in TP73 were detected in MM-468 cells. The results obtained emphasize the importance of the polyphenol gossypol as a compound that can induce cancer cell apoptosis through extrinsic apoptosis-related genes. This compound may be targeted for TNBC treatment, particularly in African-American patients.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Institute of Minority Health and Health Disparity through grants G12 MD007582 and P20 MD006738.

Availability of data and materials

The datasets used during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

Conceptualization of the study was achieved by SSM and KFAS. The research methodology was designed by SSM, HA, CC, NOZ, PM and KFAS. Formal analysis of the data was conducted by SSM and KFAS. Funding acquisition was accomplished by KFAS. Project administration was carried out by KFAS, and study resources were obtained by SSM and KFAS. Software analysis of data and figures was conducted by SSM and KFAS, and supervision of the research was conducted by KFAS. Writing of the original draft was undertaken by SSM, and writing, review and editing of the manuscript were carried out by SSM, NOZ, PM, HA, CC and KFAS. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors state that they have no competing interests.

References 1

Al-Romaih

Sadikovic

Yoshimoto

Wang

Zielenska

Squire

Decitabine-induced demethylation of 5′ CpG island in GADD45A leads to apoptosis in osteosarcoma cells

Neoplasia104714802008

10.1593/neo.08174

18472964

2373908

Albain

Unger

Crowley

Coltman

JrHershman

Racial disparities in cancer survival among randomized clinical trials patients of the Southwest oncology group

J Natl Cancer Inst1019849922009

10.1093/jnci/djp175

19584328

2724852

Alderson

Smith

Tough

Davis-Smith

Armitage

Falk

Roux

Baker

Sutherland

Din

Molecular and biological characterization of human 4-1BB and its ligand

Eur J Immunol24221922271994

10.1002/eji.1830240943

8088337

Schulze-Osthoff

Ferrari

Los

Wesselborg

Peter

Apoptosis signaling by death receptors

Eur J Biochem2544394591998

10.1046/j.1432-1327.1998.2540439.x

9688254

Mishra

Salehi

Sharifi-Rad

Pezzani

Kobarfard

Sharifi-Rad

Nigam

Programmed cell death, from a cancer perspective: An overview

Mol Diagn Ther222812952018

10.1007/s40291-018-0329-9

29560608

Wali

Masters

Thomas

Linking metabolic abnormalities to apoptotic pathways in Beta cells in type 2 diabetes

Cells22662832013

10.3390/cells2020266

24709700

3972679

Miyashita

Krajewski

Krajewska

Wang

Lin

Liebermann

Hoffman

Reed

Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo

Oncogene9179918051994

8183579

Kang

Reynolds

Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy

Clin Cancer Res15112611322009

10.1158/1078-0432.CCR-08-0144

19228717

3182268

Fulda

Targeting inhibitor of apoptosis proteins (IAPs) for cancer therapy

Anticancer Agents Med Chem85335392008

10.2174/187152008784533107

18537535

Mannhold

Fulda

Carosati

IAP antagonists: Promising candidates for cancer therapy

Drug Discov Today152102192010

10.1016/j.drudis.2010.01.003

20096368

DeSantis

Fedewa

Goding Sauer

Kramer

Smith

Jemal

Breast cancer statistics, 2015: Convergence of incidence rates between black and white women

CA Cancer J Clin6631422016

10.3322/caac.21320

26513636

Anders

Carey

Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer

Clin Breast Cancer9(Suppl 2)S73S812009

10.3816/CBC.2009.s.008

19596646

2919761

Beaumont

Leadbeater

Treatment and care of patients with metastatic breast cancer

Nurs Stand2549562011

10.7748/ns2011.06.25.40.49.c8566

21755793

Fernández

Cueva

Palomo

Ramos

de Juan

Calvo

García-Mata

García-Teijido

Peláez

García-Estévez

Novel therapeutic approaches to the treatment of metastatic breast cancer

Cancer Treat Rev3633422010

10.1016/j.ctrv.2009.10.001

19883980

Liu

Kumar

Brown

Kannappan

Tawari

Tang

Jiang

Armesilla

Darling

Wang

Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells

Br J Cancer109187618852013

10.1038/bjc.2013.534

24008666

3790184

Craig

O'Shaughnessy

Kiefer

Aldrich

Sinari

Moses

Wong

Dinh

Christoforides

Blum

Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities

Mol Cancer Ther121041162013

10.1158/1535-7163.MCT-12-0781

23171949

Cao

Sethumadhavan

Bland

Isolation of cottonseed extracts that affect human cancer cell growth

Sci Rep8104582018

10.1038/s41598-018-28773-4

29993017

6041348

Zhang

Olk

Chemical composition of defatted cottonseed and soy meal products

PLoS One10e01299332015

10.1371/journal.pone.0129933

26079931

4469676

Sharifi-Rad

Fokou

PVT

Sharopov

Martorell

Ademiluyi

Rajkovic

Salehi

Martins

Iriti

Sharifi-Rad

Antiulcer agents: From plant extracts to phytochemicals in healing promotion

Molecules23piiE17512018

10.3390/molecules23071751

30018251

Lin

Schinazi

Zhu

Birks

Carbone

Huang

Prusoff

Anti-HIV-1 activity and cellular pharmacology of various analogs of gossypol

Biochem Pharmacol462512551993

10.1016/0006-2952(93)90411-O

8347147

Janero

Burghardt

Protection of rat myocardial phospholipid against peroxidative injury through superoxide-(xanthine oxidase)-dependent, iron-promoted fenton chemistry by the male contraceptive gossypol

Biochem Pharmacol37333533421988

10.1016/0006-2952(88)90647-8

2840914

Liu

Kulp

Sugimoto

Jiang

Chang

Dowd

Wan

Lin

The (−)-enantiomer of gossypol possesses higher anticancer potency than racemic gossypol in human breast cancer

Anticancer Res2233382002

12017312

Moon

Kim

Lee

Kim

Gossypol suppresses NF-kappaB activity and NF-kappaB-related gene expression in human leukemia U937 cells

Cancer Lett2641922002008

10.1016/j.canlet.2008.01.030

18314260

Voss

Senft

Lang

Ronellenfitsch

Steinbach

Seifert

Kögel

The pan-Bcl-2 inhibitor (−)-gossypol triggers autophagic cell death in malignant glioma

Mol Cancer Res8100210162010

10.1158/1541-7786.MCR-09-0562

20587533

Zhang

Liu

Guo

Ling

Roller

Wang

Yang

Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells

Biochem Pharmacol66931032003

10.1016/S0006-2952(03)00248-X

12818369

Pang

Chen

Wang

Liu

(−)-Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signaling-mediated angiogenesis

Mol Cancer Ther107958052011

10.1158/1535-7163.MCT-10-0936

21372225

3227412

Flack

Pyle

Mullen

Lorenzo

Knazek

Nisula

Reidenberg

Oral gossypol in the treatment of metastatic adrenal cancer

J Clin Endocrinol Metab76101910241993

10.1210/jcem.76.4.8473376

8473376

Moon

Choi

Moon

Kim

Gossypol decreases tumor necrosis factor-α-induced intercellular adhesion molecule-1 expression via suppression of NF-κB activity

Food Chem Toxicol4999910052011

10.1016/j.fct.2011.01.006

21223991

Gilbert

O'Reilly

Chang

Lin

Brueggemeier

Antiproliferative activity of gossypol and gossypolone on human breast cancer cells

Life Sci5761671995

10.1016/0024-3205(95)00243-Y

7596222

Chang

Brueggemeier

Lin

Gossypol inhibits basal and estrogen-stimulated DNA synthesis in human breast carcinoma cells

Life Sci53Pl433Pl4381993

10.1016/0024-3205(93)90036-3

8255144

Chang

Wang

Huang

Shu

Sugimoto

Dowd

Wan

Lin

Induction of apoptosis by (−)-gossypol-enriched cottonseed oil in human breast cancer cells

Int J Mol Med261131192010

20514430

Lin

Yang

Zhao

Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo

Oncol Rep307317382013

10.3892/or.2013.2489

23708869

Sadahira

Sagawa

Nakazato

Uchida

Ikeda

Okamoto

Nakajima

Kizaki

Gossypol induces apoptosis in multiple myeloma cells by inhibition of interleukin-6 signaling and Bcl-2/Mcl-1 pathway

Int J Oncol45227822862014

10.3892/ijo.2014.2652

25231749

Baoleri

Dong

Zhou

Zhang

Xie

Combination of L-gossypol and low-concentration doxorubicin induces apoptosis in human synovial sarcoma cells

Mol Med Rep12592459322015

10.3892/mmr.2015.4127

26238307

Benvenuto

Mattera

Masuelli

Taffera

Andracchio

Tresoldi

Lido

Giganti

Godos

Modesti

Bei

(±)-Gossypol induces apoptosis and autophagy in head and neck carcinoma cell lines and inhibits the growth of transplanted salivary gland cancer cells in BALB/c mice

Int J Food Sci Nutr682983122017

10.1080/09637486.2016.1236077

27670669

Zhao

Pan

Lin

Huang

Cai

Ouyang

The BH3-mimetic gossypol and noncytotoxic doses of valproic acid induce apoptosis by suppressing cyclin-A2/Akt/FOXO3a signaling

Oncotarget638952389662015

10.18632/oncotarget.5731

26517515

4770749

Zhang

Liu

Tian

Griffith

Gossypol induces apoptosis in human PC-3 prostate cancer cells by modulating caspase-dependent and caspase-independent cell death pathways

Life Sci807677742007

10.1016/j.lfs.2006.11.004

17156797

Volate

Kawasaki

Hurt

Milner

Kim

White

Farrar

Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumor-initiating cells

Mol Cancer Ther94614702010

10.1158/1535-7163.MCT-09-0507

20124455

2820604

You

Wang

Sun

Zheng

Gossypol induces cell death by activating apoptosis and autophagy in HT-29 cells

Mol Med Rep16212821322017

10.3892/mmr.2017.6804

28656225

Jin

Chen

Lian

Deng

Phosphoproteomic analysis of gossypol-induced apoptosis in ovarian cancer cell line, HOC1a

Biomed Res Int20141234822014

10.1155/2014/123482

25180175

4144078

Wang

Jin

Deng

Chen

Lian

Deng

Gossypol induces apoptosis in ovarian cancer cells through oxidative stress

Mol Biosyst9148914972013

10.1039/c3mb25461e

23532321

Xin

Zhan

Xia

Zhu

Nie

Liang

Tian

ApoG2 as the most potent gossypol derivatives inhibits cell growth and induces apoptosis on gastric cancer cells

Biomed Pharmacother6788952013

10.1016/j.biopha.2012.10.016

23201009

Cheng

Zhao

Yang

Effects of gossypol acetate on apoptosis in primary cultured cells from patients with lymphoid leukemia and its synergy with dexamethasone

Zhongguo Shi Yan Xue Ye Xue Za Zhi202292342012(In Chinese)

22541072

Balakrishnan

Wierda

Keating

Gandhi

Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells

Blood112197119802008

10.1182/blood-2007-12-126946

18566329

2518898

Tang

Wang

Chen

Huang

Gossypol acetate induced apoptosis of pituitary tumor cells by targeting the BCL-2 via the upregulated microRNA miR-15a

Int J Clin Exp Med8907990852015

26309203

4538161

Karaca

Atmaca

Uzunoglu

Karabulut

Sanli

Uslu

Enhancement of taxane-induced cytotoxicity and apoptosis by gossypol in human breast cancer cell line MCF-7

J BUON144794852009

19810142

Yoshida

Niki

Jyotaki

Sanematsu

Shigemura

Ninomiya

Modulation of sweet responses of taste receptor cells

Semin Cell Dev Biol242262312013

10.1016/j.semcdb.2012.08.004

22947916

Tate

Rhodes

Segar

Driver

Pounder

Burow

Collins-Burow

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat

Breast Cancer Res14R792012

10.1186/bcr3192

22613095

3446342

Messeha

Zarmouh

Mendonca

Alwagdani

Kolta

Soliman

KFA

The inhibitory effects of plumbagin on the NF-κB pathway and CCL2 release in racially different triple-negative breast cancer cells

PLoS One13e02011162018

10.1371/journal.pone.0201116

30059519

6066199

Citalingam

Abas

Lajis

Othman

Naidu

Anti-proliferative effect and induction of apoptosis in androgen-independent human prostate cancer cells by 1,5-bis(2-hydroxyphenyl)-1,4-pentadiene-3-one

Molecules20340634302015

10.3390/molecules20023406

25690296

6272399

Chougule

Patel

Jackson

Singh

Antitumor activity of noscapine in combination with doxorubicin in triple negative breast cancer

PLoS One6e177332011

10.1371/journal.pone.0017733

21423660

3057970

Plati

Bucur

Khosravi-Far

Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities

J Cell Biochem104112411492008

10.1002/jcb.21707

18459149

2941905

Kretschmer

Sterner-Kock

Siedentopf

Schoenegg

Schlag

Kemmner

Identification of early molecular markers for breast cancer

Mol Cancer10152011

10.1186/1476-4598-10-15

21314937

3045364

Salunga

Tuggle

Gaudet

Enright

McQuary

Payette

Pistone

Stecker

Zhang

Gene expression profiles of human breast cancer progression

Proc Natl Acad Sci USA100597459792003

10.1073/pnas.0931261100

12714683

Van Poznak

Seidman

Reidenberg

Moasser

Sklarin

Van Zee

Borgen

Gollub

Bacotti

Yao

Oral gossypol in the treatment of patients with refractory metastatic breast cancer: A phase I/II clinical trial

Breast Cancer Res Treat662392482001

10.1023/A:1010686204736

11510695

Wong

Apoptosis in cancer: From pathogenesis to treatment

J Exp Clin Cancer Res30872011

10.1186/1756-9966-30-87

21943236

3197541

Zhan

Gadd45a, a p53- and BRCA1-regulated stress protein, in cellular response to DNA damage

Mutat Res5691331432005

10.1016/j.mrfmmm.2004.06.055

15603758

Tront

Willis

Huang

Hoffman

Liebermann

Gadd45a levels in human breast cancer are hormone receptor dependent

J Transl Med111312013

10.1186/1479-5876-11-131

23706118

3665690

Desjardins

Ouellette

Labrie

Simard

INHERIT BRCAsDurocher

Analysis of GADD45A sequence variations in French Canadian families with high risk of breast cancer

J Hum Genet534904982008

10.1007/s10038-008-0276-0

18350249

Takekawa

Saito

A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK

Cell955215301998

10.1016/S0092-8674(00)81619-0

9827804

Harkin

Bean

Miklos

Song

Truong

Englert

Christians

Ellisen

Maheswaran

Oliner

Haber

Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1

Cell975755861999

10.1016/S0092-8674(00)80769-2

10367887

Yasuda

Theodorakis

Subramanian

Chinnadurai

Adenovirus E1B-19K/BCL-2 interacting protein BNIP3 contains a BH3 domain and a mitochondrial targeting sequence

J Biol Chem27312415124211998

10.1074/jbc.273.20.12415

9575197

Bandyopadhyay

Zhan

Wang

Pai

Hirota

Hosobe

Takano

Saito

Furuta

Iiizumi

Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells

Cancer Res66593459402006

10.1158/0008-5472.CAN-05-3197

16740734

Vande Velde

Cizeau

Dubik

Alimonti

Brown

Israels

Hakem

Greenberg

BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore

Mol Cell Biol20545454682000

10.1128/MCB.20.15.5454-5468.2000

10891486

85997

Khan

Aljarbou

Aldebasi

Faisal

Khan

Resveratrol suppresses the proliferation of breast cancer cells by inhibiting fatty acid synthase signaling pathway

Cancer Epidemiol387657722014

10.1016/j.canep.2014.09.006

25448084

Silva

Ferreira-Strixino

Fontana

Paula

Raniero

Martin

Canevari

Apoptosis-associated genes related to photodynamic therapy in breast carcinomas

Lasers Med Sci29142914362014

10.1007/s10103-014-1547-y

24573956

Ruddle

Tumor necrosis factor (TNF-alpha) and lymphotoxin (TNF-beta)

Curr Opin Immunol43273321992

10.1016/0952-7915(92)90084-R

1329840

Rath

Aggarwal

TNF-induced signaling in apoptosis

J Clin Immunol193503641999

10.1023/A:1020546615229

10634209

Robbs

Lucena

Viola

The transcription factor NFAT1 induces apoptosis through cooperation with Ras/Raf/MEK/ERK pathway and upregulation of TNF-α expression

Biochim Biophys Acta1833201620282013

10.1016/j.bbamcr.2013.04.003

23583303

Balkwill

TNF-alpha in promotion and progression of cancer

Cancer Metastasis Rev254094162006

10.1007/s10555-006-9005-3

16951987

Szlosarek

Balkwill

Tumour necrosis factor alpha: A potential target for the therapy of solid tumours

Lancet Oncol45655732003

10.1016/S1470-2045(03)01196-3

12965278

Balkwill

Tumor necrosis factor or tumor promoting factor?

Cytokine Growth Factor Rev131351412002

10.1016/S1359-6101(01)00020-X

11900989

Luo

Maeda

Hsu

Yagita

Karin

Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression

Cancer Cell62973052004

10.1016/j.ccr.2004.08.012

15380520

Hassan

Watari

AbuAlmaaty

Ohba

Sakuragi

Apoptosis and molecular targeting therapy in cancer

Biomed Res Int20141508452014

10.1155/2014/150845

25013758

4075070

Hahne

Kataoka

Schröter

Hofmann

Irmler

Bodmer

Schneider

Bornand

Holler

French

APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth

J Exp Med188118511901998

10.1084/jem.188.6.1185

9743536

2212534

Schwarz

Valbracht

Tuckwell

von Kempis

Lotz

ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages

Blood85104310521995

7849293

Bellarosa

Bressan

Bigioni

Parlani

Maggi

Binaschi

SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line

Int J Oncol41148614942012

10.3892/ijo.2012.1551

22797667

Hingorani

Dickman

Garcia-Filion

White-Collins

Kolb

Azorsa

BIRC5 expression is a poor prognostic marker in ewing sarcoma

Pediatr Blood Cancer6035402013

10.1002/pbc.24290

22961763

Jha

Shukla

Pandey

Survivin expression and targeting in breast cancer

Surg Oncol211251312012

10.1016/j.suronc.2011.01.001

21334875

Shin

Sung

Cho

Kim

Hwang

Chung

Jung

An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and −7

Biochemistry40111711232001

10.1021/bi001603q

11170436

Ghaffari

Hashemi

Ebrahimi

Shirkoohi

BIRC5 genomic copy number variation in early-onset breast cancer

Iran Biomed J202412452016

27372966

4983680

Mahlamäki

Bärlund

Tanner

Gorunova

Höglund

Karhu

Kallioniemi

Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer

Genes Chromosomes Cancer353533582002

10.1002/gcc.10122

12378529

Baykara

Bakir

Buyru

Kaynak

Dalay

Amplification of chromosome 8 genes in lung cancer

J Cancer62702752015

10.7150/jca.10638

25663945

4317763

Gunaldi

Isiksacan

Kocoglu

Okuturlar

Gunaldi

Topcu

Karabulut

The value of serum survivin level in early diagnosis of cancer

J Cancer Res Ther145705732018

10.4103/0973-1482.171369

29893319

Kato

Kuwabara

Mitani

Shinoda

Sato

Toyama

Mitsui

Nishiwaki

Moriyama

Kudo

Fujii

Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy

Int J Cancer9592952001

10.1002/1097-0215(20010320)95:2<92::AID-IJC1016>3.0.CO;2-9

11241318

Coumar

Tsai

Kanwar

Sarvagalla

Cheung

Treat cancers by targeting survivin: Just a dream or future reality?

Cancer Treat Rev398028112013

10.1016/j.ctrv.2013.02.002

23453862

Ren

Wang

Zhang

Expression of livin, survivin, and caspase-3 in prostatic cancer and their clinical significance

Int J Clin Exp Pathol814034140392015

26823716

4713502

Yao

Wang

DAPK1 modulates a curcumin-induced G2/M arrest and apoptosis by regulating STAT3, NF-κB, and caspase-3 activation

Biochem Biophys Res Commun43475802013

10.1016/j.bbrc.2013.03.063

23545262

Yoo

Byun

Kim

Lee

Park

Rho

DAPk1 inhibits NF-κB activation through TNF-α and INF-γ-induced apoptosis

Cell Signal24147114772012

10.1016/j.cellsig.2012.03.010

22465880

Pozniak

Radinovic

Yang

McKeon

Kaplan

Miller

An anti-apoptotic role for the p53 family member, p73, during developmental neuron death

Science2893043062000

10.1126/science.289.5477.304

10894779

Melino

De Laurenzi

Vousden

p73: Friend or foe in tumorigenesis

Nat Rev Cancer26056152002

10.1038/nrc861

12154353

Huang

Liao

Yang

Chen

Jiang

Curcumol triggers apoptosis of p53 mutant triple-negative human breast cancer MDA-MB 231 cells via activation of p73 and PUMA

Oncol Lett14108010882017

10.3892/ol.2017.6273

28693277

5494799

Yamamoto

Oda

Kubota

Miyazaki

Takenouti

Nimura

Hamaguchi

Matsuda

Expression of p73 gene, cell proliferation and apoptosis in breast cancer: Immunohistochemical and clinicopathological study

Oncol Rep97297352002

12066200

Fang

Xie

Relationship between TP73 polymorphism (G4C14-A4T14) and cancer risk: A meta-analysis based on literatures

Gene48442462011

10.1016/j.gene.2011.05.022

21672615

Jung

Chae

Moon

Kang

Kim

Sohn

Park

Lee

Park

TNF superfamily gene polymorphism as prognostic factor in early breast cancer

J Cancer Res Clin Oncol1366856942010

10.1007/s00432-009-0707-0

19890662

Jarvis

Turner

Povirk

Traylor

Grant

Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C

Cancer Res54170717141994

7511048

Wang

Rao

Effect of gossypol on DNA synthesis and cell cycle progression of mammalian cells in vitro

Cancer Res4435381984

6690046

Kitada

Leone

Sareth

Zhai

Reed

Pellecchia

Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins

J Med Chem46425942642003

10.1021/jm030190z

13678404

Oliver

Miranda

Shangary

Land

Wang

Johnson

(−)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance

Mol Cancer Ther423312005

10.1186/1476-4598-4-23

15657350

100

Lei

Chen

Wang

Xia

Mao

Zong

Gossypol induces Bax/Bak-independent activation of apoptosis and cytochrome c release via a conformational change in Bcl-2

FASEB J20214721492006

10.1096/fj.05-5665fje

16935937

Figure 1.

Effect of GOSS on the viability of MM-231 and MM-468 TNBC cell lines. Cells were treated for 24 h with GOSS at concentration ranges of 0–100 µM (A) and 0–50 µM (B) in MM-231 and MM-468 cells, respectively. The graph shows the viability data expressed as percentages of cell survival compared to the control. The data points represent the mean ± SEM of three independent studies, n=4 each. The significance of the difference between the control and treated groups was determined using one-way analysis of variance (ANOVA) followed by Bonferroni's multiple comparisons test. The difference was considered significant at **P<0.01 and ****P<0.0001. GOSS, gossypol; MM-231, MDA-MB-231; MM-468, MDA-MB-468; TNBC, triple-negative breast cancer; IC₅₀, half maximal inhibitory concentration.

Figure 2.

Effect of GOSS on proliferation and colony formation in MM-231 and MM-468 TNBC cell lines. In the cell proliferation study, cells were incubated for 96 h with GOSS at concentration ranges of 0–100 µM (A) and of 0–50 µM (C) in MM-231 and MM-468 cells, respectively. For the colony formation assay, MM-231 (B) and MM-468 (D) cells were exposed to similar concentrations of GOSS for either 1 or 6 h and then washed and allowed to grow in regular cell culture media for 7 days. In both assays, each data point represents the mean ± SEM of three independent experiments, n=4 each. The significance of the difference between the different exposure periods was calculated using two-way analysis of variance (ANOVA) followed by Bonferroni's multiple comparisons test, and ****P<0.0001 indicates a statistically significant difference between 24-h vs. other exposure periods, while a non-significant difference was found between the 72- vs. 96-h exposure periods. Similarly, ****P<0.0001, ***P<0.001 and *P<0.05 indicate a statistically significant difference in the colony formation inhibition between the 1- vs. 6-h exposure periods at different concentrations. GOSS, gossypol; TNBC, triple-negative breast cancer; MM-231, MDA-MB-231; MM-468, MDA-MB-468; IC₅₀, half maximal inhibitory concentration; ns, not significant.

Figure 3.

Effect of doxorubicin on proliferation in (A) MM-231 and (B) MM-468 TNBC cell lines. Both cell lines were incubated for 72 h with doxorubicin at concentration ranges of 0–10 µM. Each point represents the mean ± SEM of two independent experiments, n=4 each. The graph shows the proliferation rate expressed as percentages compared to the control. The significance of the difference between the control and treated groups was determined using one-way analysis of variance (ANOVA) followed by Bonferroni's multiple comparisons test. The difference was considered significant at *P<0.05, ***P<0.001 and ****P<0.0001. TNBC, triple-negative breast cancer; MM-231, MDA-MB-231; MM-468, MDA-MB-468; IC₅₀, half maximal inhibitory concentration.

Figure 4.

Apoptotic effect of GOSS on (A) MM-231 and (B) MM-468 TNBC cell lines. Cells were exposed to GOSS for 24 h at concentrations ranging from 0 to 100 µM for MM-231 cells and 0–50 µM for MM-468 cells. Control cells were treated with DMSO at the highest exposure dose (<0.1%). An Annexin V-FITC apoptosis kit was used to label treated/control cells, and a FACSCalibur flow cytometer was used to analyze the percentage of apoptotic cells compared to the DMSO-treated control cells. Each data point represents the mean ± SEM of two independent studies, n=3 each. The significance of the difference between control vs. each treatment was calculated using one-way analysis of variance (ANOVA) followed by Bonferroni's multiple comparisons test. ****P<0.0001 confirmed the statistically significant difference. GOSS, gossypol; TNBC, triple-negative breast cancer; MM-231, MDA-MB-231; MM-468, MDA-MB-468; DMSO, dimethyl sulfoxide.

Figure 5.

Scatter plots for MM-231 and MM-468 TNBC cells. Cells were exposed to GOSS for 24 h at a concentration of 25 µM in MM-231 cells and 20 µM in MM-468 cells and normalized the mRNA expression of target genes for the control vs. treated MM-231 (A) and MM-468 (B) cells. Based on the threshold set (green and red lines), the plot images show the following changes in apoptosis-related gene expression: Upregulation, red dots; downregulation, green dots; no change, black dots. In both cell lines and based on the fold changes, the most upregulated genes are enumerated from 1–3, while 4–5 refer to the downregulated genes. In MM-231 cells, GADD45A, TNFRSF9 and BNIP3 were upregulated, while BIRC5 and DAPK1 were downregulated. Similarly, in MM-468 cells, TNF, GADD45A and BNIP3 were upregulated, while BIRC5 and TP73 were downregulated. GOSS, gossypol; TNBC, triple-negative breast cancer; MM-231, MDA-MB-231; MM-468, MDA-MB-468; GADD45A, growth arrest and DNA-damage-inducible 45 alpha protein; TNFRSF9, tumor necrosis factor receptor superfamily 9; BNIP3, BCL2 interacting protein 3; BIRC5, baculoviral IAP repeat containing 5; DAPK1, death-associated protein kinase; TP73, tumor protein 73.

Figure 6.

Gene expression quantification in MM-231 cells. Cells were exposed to GOSS for 24 h at a concentration of 25 µM. Normalized mRNA data indicate a significant increase in three genes (GADD45A, TNFRSF9 and BNIP3) in the GOSS-treated MM-231 cells vs. control cells, while two genes were significantly inhibited (BIRC5 and DAPK1). The data points represent the mean ± SEM of three independent studies. The significance of the difference was determined using an unpaired t-test between the resting vs. treated cells. The difference was considered significant at *P<0.05, **P<0.01 and ***P<0.001. GOSS, gossypol; MM-231, MDA-MB-231; GADD45A, growth arrest and DNA-damage-inducible 45 alpha protein; TNFRSF9, tumor necrosis factor receptor superfamily 9; BNIP3, BCL2 interacting protein 3; BIRC5, baculoviral IAP repeat containing 5; DAPK1, death-associated protein kinase.

Figure 7.

Gene expression quantification in MM-468 cells. Cells were exposed to GOSS for 24 h at a concentration of 20 µM. Normalized mRNA data indicate a significant increase in three genes (TNF, GADD45A and BNIP3) in the GOSS-treated MM-468 cells vs. control cells, while two genes were significantly inhibited (BIRC5 and TP73). The data points represent the mean ± SEM of three independent studies. The significance of the difference was determined using an unpaired t-test between the resting vs. treated cells. The difference was considered significant at *P<0.05 and **P<0.01. GOSS, gossypol; MM-468, MDA-MB-468; TNF, tumor necrosis factor; GADD45A, growth arrest and DNA-damage-inducible 45 alpha protein; BNIP3, BCL2 interacting protein 3; BIRC5, baculoviral IAP repeat containing 5; TP73, tumor protein 73.

Table I.

mRNA gene expression changes in MM-231 and MM-468 TNBC cells.

	Control vs. treated MM-231 cells			Control vs. treated MM-468 cells

Target gene	Fold changes	P-value	Target gene	Fold changes	P-value
GADD45A	+33.42	0.028	TNF	+158.98	0.023
TNFRSF9	+12.35	0.018	GADD45A	+9.22	0.005
BNIP3	+8.75	0.015	BNIP3	+4.84	0.004
BIRC5	−7.96	0.0003	BIRC5	−24.32	0.002
DAPK1	−14.79	0.0012	TP73	−8.65	0.037

The left portion of the table presents the fold changes in gene expression (+/-) in MM-231 cells following treatment with 25 µM GOSS. In contrast, the right portion presents the fold changes in gene expression (+/-) in MM-468 cells following treatment with 20 µM GOSS. MM-231, MDA-MB231, MM-468, MDA-MB-468; TNBC, triple-negative breast cancer; GOSS, gossypol; GADD45A, growth arrest and DNA-damage-inducible 45 alpha protein; TNFRSF9, tumor necrosis factor receptor superfamily member 9; BNIP3, BCL2 interacting protein 3; BIRC5, baculoviral IAP repeat containing 5; DAPK1, death-associated protein kinase; TNF, tumor necrosis factor; TP73, tumor protein 73. P<0.05 was considered as statistically significant.